BISPECIFIC ANTIBODY EXPRESSION
Send us your sequences. We’ll express and purify them on our clinically validated B-Body® bispecific antibody platform. Your lead is developed by the team that built the platform, so you know they know how to fully leverage the tool.
Most biotech programs are led by people who deeply understand their targets and biology but who don’t have a multispecific antibody engineer on the team, and, most don’t have the months it would take to design and assemble a bispecific from scratch. B-Body Express closes that gap.
The Invenra value
Invenra is at its core an antibody engineering company. When you engage us for B-Body™ Express, you effectively gain an antibody engineer on your team for the duration of your project. We’ve already designed the platform, validated the formats, optimized the purification, and learned the rules. You don’t have to read a stack of patents to figure out what works.
You bring the targets and biology. We bring the engineering. Your biologists stay focused on the science, and the bispecific you receive is one we know how to make, because we designed the platform it’s built on.
Maybe you’ve been using the same platform and approach for years and wonder why your program can’t keep up. Most teams choose between figuring it out themselves or sending sequences to a generalist CRO.
There’s an alternative: you can work with the team that invented the B-Body bispecific platform. Here’s how those options compare.
| Do it yourself | Typical CRO |  |
|
| Inputs | Lit review, patent search, AI, phone a friend | Lit review, patent search, AI, phone a friend |
Your biology expertise |
| Design | What platform? What are the key mutations? How does your antibody fit? What linkers are you using? What formats, valencies, Fc, affinity, epitopes? | What platform? What are the key mutations? How does your antibody fit? What linkers are you using? What formats, valencies, Fc, affinity, epitopes? | Multispecific antibody engineering experts help you answer these questions |
| Process | Express, purify, and characterize with whatever tools you have in your lab | Black box | A proven, well-understood process run and adapted by antibody experts |
| Output | Unknown. Time spent building new skills and workflows for a single project | You get what you get. Some projects work, some don’t | A project-specific molecule that meets your goals and is ready for downstream development |
Send us your sequences and we do the rest. Each project goes through three coordinated steps with checkpoints along the way so you always know where things stand.
DNA construction
Your sequencesVH + VL pairs for each binding arm
QC & delivery
Invenra builds itExpress in CHO cells + run 2-step purification
Purified, characterized, 100% of yield delivered
The B-Body platform supports a wide range of bispecific architectures. Most projects start with one of three families, but we support additional variants when the biology calls for them, including 1×1, 2X1, 2×2 as well as mAb and one-orm controls.
1x1
One arm per targetTwo different binding arms, one for each target. The classic bispecific. Best for situations where you want monovalent engagement of both targets.
2x1
Asymmetric valencyTwo arms binding one target, one arm binding the other. Useful when you need bivalency on one target and monovalency on the other.
2x2
Bivalent both waysTwo arms for each target. Available in both Y and X geometries. Best for biology that benefits from avidity on both sides.
B-Body Express typically produces hundreds of antibodies across a wide range of formats at >95% purity Since purity is a critical predictor of developability, you can confidently move B-Body Express molecules directly to manufacturing.
Anti-CH1 capture followed by cation exchange polishing brings final purity to >95% when starting with high quality mAbs. Data includes >1,000 molecules in a range of formats.
The B-Body® platform replaces the CH1/CL domain pair in one Fab arm with proprietary CH3 mutations. This automatically forces correct heavy-light chain pairing, creates pI asymmetry for clean polishing, and leaves a sole CH1 domain in the other arm that serves as a one-step purification handle.
The result is bispecific antibodies that express, purify, and behave like monoclonals — clinically validated for CMC and ready for downstream development.
Most programs add structured characterization beyond what’s included in the matrix screening: biophysical, binding kinetics, and formulation. We run all of it in-house. You don’t need another outsourced partner or potential in-house lab delays.
BIO
Carterra LSA high-throughput binding kinetics and epitope diversity, validated cell binding analysis, in silico liability scanning, mass spec for intact mass confirmation, full developability assay panel, and high-concentration formulation optimization.
DEV
Expression and purity, thermal stability, self-association, aggregation, solubility, immunogenicity risk, viscosity, each measured with a validated technique. The full developability data sits behind every lead candidate we hand off.
“The team at Invenra is highly professional, timely with milestones, demonstrate clear expertise and scientific rigor, and offer an extraordinarily unique platform that has yielded high-confidence results, despite an exceedingly challenging target.”
“Invenra and its technology are top-notch. I have and will continue to recommend the Invenra team to anyone seeking novel antibody discovery, bispecific and trispecific antibody development, and novel ADC development.”
"Top-tier platform combined with top-tier people. A team that has collaborated to drive our programs forward with speed and scientific rigor, even providing services like specialized in vitro assays and efficacy models."
"The level of customization and partnership support is unparalleled relative to the other groups we evaluated for our company."
“We have worked with over 20 platforms, and the B-Body was the highest-yielding, easiest to work with bispecific platform.”